Freedom Investing in Review (June 2022)
with No Comments

This quarter, we saw that in 1-year returns ending June 30, 2022, Developed Freedom Investing had a -1.19% disadvantage, Emerging Market Freedom Investing had a +0.46% advantage, and Overall Freedom Investing had a -0.12% disadvantage.

This Month, Here’s How We Tilted (June 2022)
with No Comments

This month, the forward P/E ratios showed considerable variation with many sectors returning to a fairer valuation.

This Month, We Tilted Away from Singapore (April 2022)
with No Comments

Singapore is approximately 37.6% in the Financial sector and has yet to increase its domestic interest rates.

Freedom Investing in Review (March 2022)
with No Comments

This quarter, we saw that in 1-year returns ending March 31, 2022, Developed Freedom Investing had a +1.44% advantage, Emerging Market Freedom Investing had a +2.07% advantage, and Overall Freedom Investing had a +1.28% advantage.

An Overview of Our Allocation Changes (March 2022)
with No Comments

We are constantly reviewing our portfolios’ asset allocations in order to bring them more in line with our Investment Committee’s best practices. Here is a summary of our recent changes.

Transaction Fees for Foreign Issues Changes Individual Foreign Strategy (January 2022)
with No Comments

At the start of the year, purchases of all of these securities had no transaction fee at Charles Schwab. However in December 2021, Schwab added a transaction fee to some of the holdings.

Updates to Schwab Institutional Intelligent Portfolios Limited Fund Selection
with No Comments

Now that the Franklin Templeton funds have been added to the Institutional Intelligent Portfolios platform, we are updating our allocations to use the cheaper funds as their primary targets.

Changes to Our Technology, Mid Cap, & Small Cap Allocations (February 2022)
with No Comments

A Technology correction may not happen, but moving more into Mid and Small Cap Value may help allocations even if it doesn’t.

U.S. Investing in Review (December 2021)
with No Comments

We anticipated Consumer Staples to have a lower expected return but a larger risk-adjusted return and we expected Biotechnology to have very volatile returns with lower correlations to the other sectors. Both of those things happened in 2021.

Swap to Franklin Funds Saved Clients Over $100,000
with No Comments

The estimated advantage of Franklin funds during 2021 was 0.40% or $118,955.

Individual Foreign Health Care in Review (December 2021)
with No Comments

An initial equal weight strategy of these 26 companies implemented on January 1, 2021 and held without further buys or sells through December 31, 2021 had a +8.64% advantage over the foreign healthcare benchmark.

Freedom Investing in Review (December 2021)
with No Comments

This quarter, we saw that in 1-year returns ending December 31, 2021, Developed Freedom Investing had a -0.12% disadvantage, Emerging Market Freedom Investing had a +1.27% advantage, and Overall Freedom Investing had a +0.21% advantage.

Freedom Investing in Review (September 2021)
with No Comments

This quarter, we saw that in 1-year returns ending September 30, 2021, Developed Freedom Investing had a +0.70% advantage, Emerging Market Freedom Investing had a +1.64% advantage, and Overall Freedom Investing had a +0.71% advantage.

Freedom Investing in Review (June 2021)
with No Comments

This article is part of my series where I review how Freedom Investing performs for the quarter.

Updates to Our Bond Allocation (April 2021)
with No Comments

Recently, we lowered the duration of our U.S. Bond portfolio and increased the amount which is inflation protected. This article explains the reasons for this change.

Freedom Investing in Review (March 2021)
with No Comments

While many have been following the domestic returns and recovery, fewer investors know how well foreign investments did this past year.

An Overview of Our Allocation Changes (March 2021)
with No Comments

We are constantly reviewing our portfolios’ asset allocations in order to bring them more in line with our Investment Committee’s best practices. Here is a summary of our recent changes.

2021 Index of Economic Freedom: Taiwan
with No Comments

This means that in addition to the overall Emerging Market funds, we will have country-specific Emerging Market allocations to both Taiwan and Chile.

2021 Index of Economic Freedom: Hong Kong
with No Comments

No one knows what the future holds for Hong Kong, but we needed to make a decision on whether it has a place in our Freedom Investing.

New Funds for United Kingdom, Hong Kong, and Canada
with No Comments

We would expect the switch to Frankiln funds to save our clients 0.11% annually due to the lower expense ratio.

The Case for Investing in Foreign Health Care
with No Comments

When reviewing our Foreign allocations, we discovered that the foreign Health Care sector has shown high risk-adjusted performance.

2021 Performance Report for Marotta’s Gone-Fishing Portfolios (2012-2020)
with No Comments

Our Gone-Fishing Portfolios are free to use portfolios that take advantage of the no-transaction-fee, low-cost ETFs or mutual funds of each major custodian. Over the years, we’ve changed the funds and the allocations as new research or securities reveal improvements.

We Added Individual Stocks to Our Foreign Allocations (January 2021)
with No Comments

We believe these 26 companies will be an effective weight to add foreign healthcare to our portfolios.

We Added a Sector Tilt to our Foreign Dynamic Tilt (November 2020)
with No Comments

We hope this small increased exposure to foreign healthcare will help capture some of the efficiencies we believe to have found.

This Month, We Removed the Energy Overweight from Our Allocations (October 2020)
with No Comments

We believe that holding on to Energy and waiting for it to recover might mean missing out on greater gains elsewhere.

We Added 2 New U.S. Stock Sectors to Our Allocations
with No Comments

We decided to add two new sectors after generating several hundred efficient frontier graphs of various United States classifications, industries, and sectors over a variety of time periods.

Risk-Return Analysis of Freedom Investing
with No Comments

In this article, I am reviewing the quantitative measurements and performance metrics of Freedom Investing to see how its risk and return compare to the EAFE Index, its benchmark.

Hong Kong Still Has a Place in Freedom Investing
with No Comments

Hong Kong has always been an anomaly: a tiny, extremely free country with an expiration date in 2047.

More Freedom Investing Added to Marotta’s Schwab IIP Asset Allocation (June 2020)
with No Comments

As a result of new fund additions, we added five new country-specific funds to our Schwab Institutional Intelligent Portfolio asset allocations.

A 25-Year Review of Freedom Investing
with No Comments

These findings together demonstrate how Economic Freedom seems to have been a valid factor for higher expected returns than investing in the EAFE Index alone.

This Month, We Leveled Our Small Cap Value Allocation (June 2020)
with No Comments

As we are still in the midst of COVID-19 quarantines, we will have to wait to see what continuing or lifting restrictions actually does to companies, their expected earnings, and their market pricing.

Energy Stocks Have Been Disappointing Recently (April 2020)
with No Comments

Diversification means always having something to complain about. Recently, it has been energy.

This May 2020, Our Dynamic Tilt Tilted Away from Energy
with No Comments

For many whose Energy sector has experienced large losses, lowering your sector allocation might effectively mean holding onto the shares that you currently own without adding more.

Like what you read? Subscribe to our newsletter!